Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIVID EAST: Eylea in Diabetic Macular Edema
NCT01783886Phase 3Completed
- Sponsor
- Bayer
- Start
- Feb 2013
- Primary completion
- Mar 2015
- Countries
- 4
01
Overview
A Phase 3 trial of aflibercept in diabetic macular edema (DME), sponsored by Bayer. Started Feb 2013; status: completed.
02
Drugs
aflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT01783886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01783886.